MSD set to acquire novel antibody for B-cell malignancies
European Pharmaceutical Review
AUGUST 12, 2024
Progress in immunotherapy drug development In June, the US Food and Drug Administration (FDA) authorised an immunotherapy combination to treat endometrial cancer. The bispecific antibody has shown potential to generate “significant and sustained reductions in B-cell populations”.
Let's personalize your content